Fresenius stock holds on earnings metrics and market value
Published on 07/21/2026 at 21:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius stock (DE0005785604) is still priced around a major healthcare turnaround story, with the latest available company reporting showing revenue of EUR 21.6 billion in fiscal 2025 and an adjusted operating margin of 15.0% for the same period. The company also reported adjusted net income of EUR 1.3 billion in fiscal 2025, giving investors a clear baseline for the current valuation debate.
Fiscal 2025 still defines the setup
Fresenius said fiscal 2025 revenue reached EUR 21.6 billion, while adjusted net income came in at EUR 1.3 billion. Those figures matter because they frame the stock around a business that is still large, profitable, and comparatively defensive within European healthcare.
The margin detail is just as important: an adjusted operating margin of 15.0% in fiscal 2025 shows the group is no longer just a volume story. For investors, that margin is the number that links operational execution to the share-price debate.
Margin stays the focus
On the market side, Fresenius shares trade on Xetra, the most relevant venue for the German-listed name, and the stock remains a Frankfurt large-cap reference point for healthcare exposure. That matters because valuation tends to react faster when a company pairs stable earnings with visible margin progress.
The most useful comparison is the relationship between scale and profitability: EUR 21.6 billion in fiscal 2025 revenue against EUR 1.3 billion in adjusted net income leaves room for further earnings leverage if margins hold. The 15.0% adjusted operating margin is the clearest evidence of that leverage.
Fresenius fiscal 2025 numbers in context
Use the latest investor material to compare revenue, operating margin, and net income against the prior year trend.
Fresenius Kabi matters
Fresenius Kabi remains one of the most relevant businesses inside the group because it links hospital products, nutrition, and infusion therapies to recurring demand. In a company with EUR 21.6 billion in fiscal 2025 revenue, segment execution is what determines whether the margin story stays intact.
That is why the product side matters even in a thin-news setup. The stock case is not about a single headline event; it is about whether the operating numbers keep supporting the 15.0% adjusted operating margin and the EUR 1.3 billion adjusted net income base.
Xetra price backdrop
Fresenius stock is quoted on Xetra in EUR, which keeps the German price signal clean for international readers. The share should be read against the companys fiscal 2025 scale, margin, and net income profile rather than against a one-day narrative alone.
Fresenius share data
- Company: Fresenius SE & Co. KGaA
- ISIN: DE0005785604
- Ticker: XETRA: FRE
- Trading venue: Xetra
- Sector / Industry: Healthcare / Healthcare Equipment & Supplies
- Index membership: DAX
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
